These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8230097)

  • 21. Interdependence of Inhibitor Recognition in HIV-1 Protease.
    Paulsen JL; Leidner F; Ragland DA; Kurt Yilmaz N; Schiffer CA
    J Chem Theory Comput; 2017 May; 13(5):2300-2309. PubMed ID: 28358514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
    Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
    J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Probing structure-function relationships in human immunodeficiency virus type 1 protease via molecular dynamics simulation.
    Harte WE; Beveridge DL
    Methods Enzymol; 1994; 241():178-95. PubMed ID: 7854178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The discovery, characterization and crystallographically determined binding mode of an FMOC-containing inhibitor of HIV-1 protease.
    Rutenber EE; De Voss JJ; Hoffman L; Stroud RM; Lee KH; Alvarez J; McPhee F; Craik C; Ortiz de Montellano PR
    Bioorg Med Chem; 1997 Jul; 5(7):1311-20. PubMed ID: 9377091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains.
    Wannberg J; Sabnis YA; Vrang L; Samuelsson B; Karlén A; Hallberg A; Larhed M
    Bioorg Med Chem; 2006 Aug; 14(15):5303-15. PubMed ID: 16621572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structure-aided design of novel inhibitors of HIV protease based on a benzodiazepine scaffold.
    Schimer J; Cígler P; Veselý J; Grantz Šašková K; Lepšík M; Brynda J; Rezáčová P; Kožíšek M; Císařová I; Oberwinkler H; Kraeusslich HG; Konvalinka J
    J Med Chem; 2012 Nov; 55(22):10130-5. PubMed ID: 23050738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors.
    Andersson HO; Fridborg K; Löwgren S; Alterman M; Mühlman A; Björsne M; Garg N; Kvarnström I; Schaal W; Classon B; Karlén A; Danielsson UH; Ahlsén G; Nillroth U; Vrang L; Oberg B; Samuelsson B; Hallberg A; Unge T
    Eur J Biochem; 2003 Apr; 270(8):1746-58. PubMed ID: 12694187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors.
    Calugi C; Guarna A; Trabocchi A
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):936-43. PubMed ID: 22803674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors of the C(2)-symmetric HIV-1 protease: nonsymmetric binding of a symmetric cyclic sulfamide with ketoxime groups in the P2/P2' side chains.
    Hultén J; Andersson HO; Schaal W; Danielson HU; Classon B; Kvarnström I; Karlén A; Unge T; Samuelsson B; Hallberg A
    J Med Chem; 1999 Oct; 42(20):4054-61. PubMed ID: 10514275
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 4-hydroxy-5,6-dihydropyrones. 2. Potent non-peptide inhibitors of HIV protease.
    Tait BD; Hagen S; Domagala J; Ellsworth EL; Gajda C; Hamilton HW; Prasad JV; Ferguson D; Graham N; Hupe D; Nouhan C; Tummino PJ; Humblet C; Lunney EA; Pavlovsky A; Rubin J; Gracheck SJ; Baldwin ET; Bhat TN; Erickson JW; Gulnik SV; Liu B
    J Med Chem; 1997 Nov; 40(23):3781-92. PubMed ID: 9371244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'.
    Ax A; Schaal W; Vrang L; Samuelsson B; Hallberg A; Karlén A
    Bioorg Med Chem; 2005 Feb; 13(3):755-64. PubMed ID: 15653343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
    Qiu X; Zhao GD; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
    Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
    Blum A; Böttcher J; Heine A; Klebe G; Diederich WE
    J Med Chem; 2008 Apr; 51(7):2078-87. PubMed ID: 18348517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of human immunodeficiency virus-1 protease by a C2-symmetric phosphinate. Synthesis and crystallographic analysis.
    Abdel-Meguid SS; Zhao B; Murthy KH; Winborne E; Choi JK; DesJarlais RL; Minnich MD; Culp JS; Debouck C; Tomaszek TA
    Biochemistry; 1993 Aug; 32(31):7972-80. PubMed ID: 8347601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
    Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
    J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.
    Romines KR; Watenpaugh KD; Howe WJ; Tomich PK; Lovasz KD; Morris JK; Janakiraman MN; Lynn JC; Horng MM; Chong KT
    J Med Chem; 1995 Oct; 38(22):4463-73. PubMed ID: 7473573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases.
    Chen Z; Li Y; Chen E; Hall DL; Darke PL; Culberson C; Shafer JA; Kuo LC
    J Biol Chem; 1994 Oct; 269(42):26344-8. PubMed ID: 7929352
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A symmetric inhibitor binds HIV-1 protease asymmetrically.
    Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
    Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.